Intraoperative Radiation Therapy Market - By Technology: Electron Beam IORT, X-Ray IORT, Hybrid Systems; By Application: Breast Cancer, Colorectal Cancer, Gynecological Cancer, Pancreatic Cancer, Others (Sarcomas, Head & Neck); By End User: Hospitals, Specialty Cancer Centers, Academic & Research Institutes; By Region: North America, Europe, Asia-Pacific Latin America and Others
1 | Market Overview
The global intraoperative radiation therapy (IORT) market is rapidly expanding due to the increasing prevalence of cancer and the demand for precise, time-efficient treatment options. IORT provides a concentrated dose of radiation directly to the tumor site during surgery, reducing exposure to nearby healthy tissues. It is commonly utilized in treating breast, colorectal, pancreatic, and gynecological cancers.
The integration of IORT into cancer treatment protocols enables clinicians to reduce the number of overall radiation therapy cycles, enhance local tumor control, and improve patient convenience. Advances in technology, such as mobile linear accelerators (LINACs), low-energy X-ray systems, and improved shielding protocols, are increasing the accessibility and effectiveness of IORT procedures.
2 | Market Size and Forecast
|
Year |
Market Value (USD Billion) |
Notes |
|
2019 |
1.06 |
Historical benchmark |
|
2024 |
1.58 |
Five-year CAGR 8.3% |
|
2031 |
3.06 |
Seven-year CAGR 9.9% |
The market is projected to almost double by 2031, supported by oncology workflow improvements, growing cancer surgical volumes, and innovations in compact IORT delivery systems.
3 | Key Market Drivers
4 | Market Challenges
5 | Competitive Landscape
The IORT market is moderately consolidated, featuring a few major companies alongside several innovative players providing platform-specific solutions.
Market Share Estimates (2024):
|
Company |
Estimated Market Share |
Key Products |
|
Carl Zeiss Meditec |
33% |
INTRABEAM® System (X-ray-based IORT) |
|
S.I.T. Sordina |
21% |
LIAC® HWL and NOVAC® electron IORT systems |
|
GMV Innovating Solutions |
17% |
Radiance® platform for multidisciplinary OR integration |
|
IntraOp Medical |
14% |
Mobetron® LINAC system |
|
Others (Isoray, BrainLab, regional suppliers) |
15% |
Hybrid systems and specialized oncology tools |
6 | Market Segmentation
By Technology:
By Application:
By End User:
By Region:
7 | Strategic Outlook
IORT is increasingly seen as an integral part of organ-preserving and ambulatory oncology care. Strategic growth will depend on flexible IORT suite designs, bundled device-service models, and evidence-based clinical trials that support broader insurance coverage.
Need help?
Chat with our team in a minute.